Bridgeway Capital Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Bridgeway Capital Management’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-110	Closed	-$42K	–	1411
2019 Q1	$42K	Sell	110 -168	-60%	-$56.3K	﹤0.01%	1320
2018 Q4	$103K	Hold	278	–	–	﹤0.01%	1300
2018 Q3	$120K	Hold	278	–	–	﹤0.01%	1375
2018 Q2	$101K	Hold	278	–	–	﹤0.01%	1361
2018 Q1	$127K	Hold	278	–	–	﹤0.01%	1309
2017 Q4	$160K	Hold	278	–	–	﹤0.01%	1297
2017 Q3	$210K	Hold	278	–	–	﹤0.01%	1276
2017 Q2	$237K	Buy	+278	New	+$203K	﹤0.01%	1252
2015 Q4	–	Sell	-63	Closed	-$92K	–	1506
2015 Q3	$92K	Hold	63	–	–	﹤0.01%	1400
2015 Q2	$140K	Buy	63 +31	+97%	+$97.2K	﹤0.01%	1404
2015 Q1	$94K	Hold	32	–	–	﹤0.01%	1419
2014 Q4	$105K	Hold	32	–	–	﹤0.01%	1386
2014 Q3	$112K	Hold	32	–	–	﹤0.01%	1419
2014 Q2	$122K	Buy	32 +5	+19%	+$18.8K	﹤0.01%	1385
2014 Q1	$110K	Hold	27	–	–	﹤0.01%	1380
2013 Q4	$100K	Sell	27 -27	-50%	-$102K	﹤0.01%	1356
2013 Q3	$211K	Buy	+54	New	+$405K	0.01%	1306

Other funds holding FRTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Bridgeway Capital Management's FRTX Position: Q2 2019 in Review

Bridgeway Capital Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2019, closing a stake of 110 shares — an estimated $42K sold.

Bridgeway Capital Management first reported a position in FRTX in Q3 2013 and held it in 17 quarters. The position peaked at $237K in Q2 2017. 22 funds tracked by Wall St. Rank hold FRTX as of Q2 2019.

Bridgeway Capital Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Bridgeway Capital Management sold 110 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $42K.
Bridgeway Capital Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2013 and held it in 17 quarters.
Bridgeway Capital Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $237K in Q2 2017.
22 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Bridgeway Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.